FinDogFinDog
Friday, October 30, 2026Closing data · 4:00 PM ET
English
Log in

EW

Edwards LifesciencesNYSE · Health Care Equipment · Health Care
Previous close
92.01
Change
−2.43 / −2.57%
FinDog View
Neutral
52-Week Range ?
74.66 – 96.29
P/E (TTM) ?
53.7
Forward P/E ?
31.0
Based on consensus earnings for the next 12 months
Market Cap
$53.6B
1M
+6.59%
S&P 500 −0.91% over same period
Volume / Avg Volume
6.0M / 3.0M
2.03× average
Latest earnings analysisFY2026 Q2Reported 2026-07-23

Edwards Lifesciences Q2 FY26: sales up 13.6%, adjusted EPS $0.78

Edwards beat its own sales guidance and edged past the $0.7627 adjusted EPS consensus, so the operating story is strong even though GAAP EPS fell to $0.42 from $0.56. The gap between $0.42 and $0.78 is mostly a $188.2 million tax charge, not a change in the business. Read revenue growth and adjusted EPS as the operating signal here, and treat GAAP net income as a one-off tax story.

Read the full analysis →
Revenue$1.74BYoY +13.60%
EPS (non-GAAP)$0.78Beatest. $0.76
Next-quarter revenue guidance$1.67B ±2.4%YoY −4.10%
Next-day move−1.42%

Price History

Closing price · USD1M6M1Y5Y
7580859095100EFY26 Q2 EarningsEFY26 Q1 EarningsEFY25 Q4 EarningsEFY25 Q3 Earnings2025-102026-012026-052026-082026-10

Historical P/E

Close ÷ trailing four-quarter EPS · Period median 32.11M6M1Y5Y
02040602023-082024-062025-032026-012026-10

Recent Earnings

Click to read the FinDog analysis
PeriodReportedRevenueEPS Actual / Est.Next-Day MoveAnalysis

Next Earnings

Date and consensus from the earnings calendar; the analysis is generated automatically after the releaseEarnings Calendar →
Report date
2026-11-04
in 3 days · After hours
Consensus EPS
$0.76
Last quarter EPS $0.78
Avg. next-day move over the last 6 reports
±3.9%

Decision Panel

Trends · Valuation · Earnings reaction · Guidance credibility — all from company filings and market data
Valuation
P/E is at percentile 100 of its 5-year rangeExpensive
5-year range 10.2 – 49.8 · Median 32.1
Last 4 quarters: $1.2B in buybacks + $0 in dividends, 2.25% of market cap combined
P/E (TTM)
53.7
P/B
5.1
P/S
8.3
PEG
3.62
Earnings Reaction
Over the last 6 reports, the stock moved ±3.9% on average on the first trading day after, rising 4 times
Most recent −1.42%
Guidance Credibility
Of the last 2 next-quarter revenue guides, 2 were met; actual results averaged 3.6% above guidance
Volatility & Correlation
1-year beta 0.55 · Correlation with S&P 500 0.28Low beta
Annualized volatility 25% vs. 13% for the S&P 500
Insider Trading
View all →
Last 90 days · Open-market buys and sells by officers and directors · Amounts in USD millions
Buy 0 · $0.00MSell 7 · $3.5MNet selling $3.5M
  • 10-08Lippis Daniel J.CVP, TAVRSell$0.05M619 shares · Avg price 85.65
  • 09-11Lippis Daniel J.CVP, TAVRSell$0.05M619 shares · Avg price 87.51
  • 08-31Dahl Andrew M.SVP, Corporate ControllerSell$0.05M544 shares · Avg price 91.06
  • 08-28Bruls AnnetteCVP, EMEACLASell$0.24M2,644 shares · Avg price 89.98
  • 08-26Markowitz WayneCVP, JAPACSell$0.11M1,240 shares · Avg price 91.47
  • 08-26Chopra DaveenCVP, TMTT, Surgical & IHFMSell$2.9M31,800 shares · 2 trades · Avg price 91.02
  • 08-11Lippis Daniel J.CVP, TAVRSell$0.06M619 shares · Avg price 92.03
Multi-Quarter Financial Trends
View all quarters →
Last 12 quarters · As reported by the company
QuarterRevenue ($B)YoYGross MarginOperating Income ($B)Net Income ($B)Free Cash Flow ($B)EPS
FY2026 Q21.74+13.6%77.5%0.510.240.590.42
FY2026 Q11.65+16.7%78.0%0.480.38-0.020.66
FY2025 Q41.57+13.3%78.1%0.150.090.350.16
FY2025 Q31.55+14.7%77.8%0.310.290.520.50
FY2025 Q21.53+11.9%77.5%0.410.330.240.56
FY2025 Q11.41+6.2%78.7%0.390.360.220.61
FY2024 Q41.39+9.4%——0.39-0.180.65
FY2024 Q31.35+8.9%80.6%0.353.070.305.13
FY2024 Q21.37+7.1%79.9%0.370.370.290.61
FY2024 Q11.33+8.9%78.4%0.350.35-0.120.58
FY2023 Q41.27+194.6%——0.370.050.61
FY2023 Q31.24−5.7%79.8%0.370.380.360.63

Peers

Largest by market cap in the sector · Latest quarterView Health Care sector →
TickerCompanyMarket CapP/ERevenue YoYGross Margin1MView